rs2737701

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_014363.6(SACS):​c.10338G>A​(p.Gln3446Gln) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.998 in 1,613,474 control chromosomes in the GnomAD database, including 802,886 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.99 ( 74172 hom., cov: 31)
Exomes 𝑓: 1.0 ( 728714 hom. )

Consequence

SACS
NM_014363.6 synonymous

Scores

3

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:14

Conservation

PhyloP100: -1.13

Publications

15 publications found
Variant links:
Genes affected
SACS (HGNC:10519): (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]
SACS Gene-Disease associations (from GenCC):
  • Charlevoix-Saguenay spastic ataxia
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Myriad Women's Health, Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia, Laboratory for Molecular Medicine, Orphanet

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_014363.6, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 13-23333538-C-T is Benign according to our data. Variant chr13-23333538-C-T is described in ClinVar as Benign. ClinVar VariationId is 130200.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.13 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.993 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_014363.6. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SACS
NM_014363.6
MANE Select
c.10338G>Ap.Gln3446Gln
synonymous
Exon 10 of 10NP_055178.3
SACS
NM_001437336.1
c.10365G>Ap.Gln3455Gln
synonymous
Exon 11 of 11NP_001424265.1A0A804HIQ1
SACS
NM_001278055.2
c.9897G>Ap.Gln3299Gln
synonymous
Exon 8 of 8NP_001264984.1

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SACS
ENST00000382292.9
TSL:5 MANE Select
c.10338G>Ap.Gln3446Gln
synonymous
Exon 10 of 10ENSP00000371729.3Q9NZJ4-1
SACS
ENST00000455470.6
TSL:1
c.2432-4054G>A
intron
N/AENSP00000406565.2H0Y6M8
SACS
ENST00000682944.1
c.10365G>Ap.Gln3455Gln
synonymous
Exon 11 of 11ENSP00000507173.1A0A804HIQ1

Frequencies

GnomAD3 genomes
AF:
0.987
AC:
150127
AN:
152098
Hom.:
74116
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.955
Gnomad AMI
AF:
1.00
Gnomad AMR
AF:
0.996
Gnomad ASJ
AF:
1.00
Gnomad EAS
AF:
1.00
Gnomad SAS
AF:
1.00
Gnomad FIN
AF:
1.00
Gnomad MID
AF:
0.997
Gnomad NFE
AF:
1.00
Gnomad OTH
AF:
0.995
GnomAD2 exomes
AF:
0.996
AC:
249772
AN:
250664
AF XY:
0.997
show subpopulations
Gnomad AFR exome
AF:
0.953
Gnomad AMR exome
AF:
0.998
Gnomad ASJ exome
AF:
1.00
Gnomad EAS exome
AF:
1.00
Gnomad FIN exome
AF:
1.00
Gnomad NFE exome
AF:
1.00
Gnomad OTH exome
AF:
0.997
GnomAD4 exome
AF:
0.999
AC:
1459308
AN:
1461258
Hom.:
728714
Cov.:
52
AF XY:
0.999
AC XY:
726061
AN XY:
726944
show subpopulations
African (AFR)
AF:
0.957
AC:
32029
AN:
33454
American (AMR)
AF:
0.997
AC:
44586
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
1.00
AC:
26116
AN:
26118
East Asian (EAS)
AF:
1.00
AC:
39676
AN:
39676
South Asian (SAS)
AF:
1.00
AC:
86215
AN:
86232
European-Finnish (FIN)
AF:
1.00
AC:
53360
AN:
53360
Middle Eastern (MID)
AF:
0.997
AC:
5748
AN:
5768
European-Non Finnish (NFE)
AF:
1.00
AC:
1111397
AN:
1111560
Other (OTH)
AF:
0.997
AC:
60181
AN:
60376
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
120
241
361
482
602
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
21664
43328
64992
86656
108320
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.987
AC:
150242
AN:
152216
Hom.:
74172
Cov.:
31
AF XY:
0.987
AC XY:
73466
AN XY:
74430
show subpopulations
African (AFR)
AF:
0.955
AC:
39661
AN:
41534
American (AMR)
AF:
0.996
AC:
15210
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
1.00
AC:
3470
AN:
3470
East Asian (EAS)
AF:
1.00
AC:
5172
AN:
5172
South Asian (SAS)
AF:
1.00
AC:
4823
AN:
4824
European-Finnish (FIN)
AF:
1.00
AC:
10620
AN:
10620
Middle Eastern (MID)
AF:
0.997
AC:
293
AN:
294
European-Non Finnish (NFE)
AF:
1.00
AC:
67982
AN:
68002
Other (OTH)
AF:
0.995
AC:
2099
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
92
184
277
369
461
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
914
1828
2742
3656
4570
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.993
Hom.:
33334
Bravo
AF:
0.985
Asia WGS
AF:
0.996
AC:
3465
AN:
3478
EpiCase
AF:
1.00
EpiControl
AF:
1.00

ClinVar

ClinVar submissions
Significance:Benign
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
-
5
Charlevoix-Saguenay spastic ataxia (5)
-
-
4
not specified (4)
-
-
3
not provided (3)
-
-
1
Hereditary spastic paraplegia (1)
-
-
1
Spastic paraplegia (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.80
CADD
Benign
0.16
DANN
Benign
0.36
PhyloP100
-1.1
Mutation Taster
=94/6
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

Publications

Other links and lift over

dbSNP: rs2737701;
hg19: chr13-23907677;
COSMIC: COSV108223218;
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.